نتائج البحث - Cornelia Quadt

  • يعرض 1 - 16 نتائج من 16
تنقيح النتائج
  1. 1
    Phase I study of alpelisib (BYL719), an α‐specific PI3K inhibitor, in Japanese patients with advanced solid tumors

    Phase I study of alpelisib (BYL719), an α‐specific PI3K inhibitor, in Japanese patients with advanced solid tumors حسب Yuichi Ando, Satoru Iwasa, Shunji Takahashi, Hideo Saka, Tomoyuki Kakizume, Kazuto Natsume, Naoko Suenaga, Cornelia Quadt, Yasuhide Yamada

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Phase I dose‐escalation study of buparlisib (<scp>BKM</scp>120), an oral pan‐class I <scp>PI</scp>3K inhibitor, in Japanese patients with advanced solid tumors

    Phase I dose‐escalation study of buparlisib (<scp>BKM</scp>120), an oral pan‐class I <scp>PI</scp>3K inhibitor, in Japanese patients with advanced solid tumors حسب Yukio Ando, Megumi Inada‐Inoue, Ayako Mitsuma, Takayuki Yoshino, Atsushi Ohtsu, Naoko Suenaga, Masahiko Sato, Tomoyuki Kakizume, Matthew Robson, Cornelia Quadt, Toshihiko Doi

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

    PI3K inhibitors as new cancer therapeutics: implications for clinical trial design حسب Cristian Massacesi, Emmanuelle di Tomaso, Patrick Urban, Caroline Germa, Cornelia Quadt, Lucia Trandafir, Paola Aimone, Nathalie Fretault, Bharani Dharan, Ranjana Tavorath, Samit Hirawat

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models

    NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models حسب Michael Rugaard Jensen, Joseph Schoepfer, Thomas Radimerski, Andrew J. Massey, Chantale T. Guy, Josef Brueggen, Cornelia Quadt, Alan Buckler, Robert Cozens, Martin J. Drysdale, Carlos Garcı́a-Echeverrı́a, Patrick Chêne

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer

    Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer حسب Zev A. Wainberg, Adrian Anghel, Amy M. Rogers, Amrita J. Desai, Ondrej Kalous, Dylan Conklin, Raul Ayala, Neil A. O’Brien, Cornelia Quadt, Mikhail Akimov, Dennis J. Slamon, Richard S. Finn

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct

    T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct حسب Bernd Schlereth, Cornelia Quadt, Torsten Dreier, Peter Kufer, Grit Lorenczewski, Nadja Prang, Christian Brandl, Sandra Lippold, KATHY E. COBB, Kathleen M. Brasky, Eugen Leo, Ralf C. Bargou, Krishna K. Murthy, Patrick A. Baeuerle

    منشور في 2005
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth

    The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth حسب Edward B. Garon, Richard S. Finn, Habib Hamidi, Judy Dering, Sharon Pitts, Naeimeh Kamranpour, Amrita J. Desai, Wylie Hosmer, Susan Ide, Emin Avşar, Michael Rugaard Jensen, Cornelia Quadt, Manway Liu, Steven M. Dubinett, Dennis J. Slamon

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors

    First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors حسب Cristiana Sessa, Geoffrey I. Shapiro, Kapil N. Bhalla, Carolyn D. Britten, Karen S. Jacks, Monica Mita, Vali Papadimitrakopoulou, Tim Pluard, Thomas A. Samuel, Mikhail Akimov, Cornelia Quadt, Cristina Fernandez‐Ibarra, Hong Lü, Stuart Bailey, Sandra Chica, Udai Banerji

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Alpelisib Plus Fulvestrant in <i>PIK3CA</i>-Altered and <i>PIK3CA</i>-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer

    Alpelisib Plus Fulvestrant in <i>PIK3CA</i>-Altered and <i>PIK3CA</i>-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer حسب Dejan Juric, Filip Janků, Jordi Rodón, Howard A. Burris, Ingrid A. Mayer, Martin Schüler, Ruth Seggewiß-Bernhardt, Marta Gil-Martín, Mark R. Middleton, José Baselga, Douglas Bootle, David Demanse, Lars Blumenstein, Karl Schumacher, Alan Huang, Cornelia Quadt, Hope S. Rugo

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft

    89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft حسب Thijs H. Oude Munnink, Maarten A. de Korte, Wouter B. Nagengast, Hetty Timmer‐Bosscha, Carolina P. Schröder, Johan R. de Jong, Guus A.M.S. van Dongen, Michael Rugaard Jensen, Cornelia Quadt, Marjolijn N. Lub–de Hooge, Elisabeth G.E. de Vries

    منشور في 2009
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in <i>PIK3CA</i>-Altered Solid Tumors: Results From the First-in-Human Study

    Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in <i>PIK3CA</i>-Altered Solid Tumors: Results From the First-in-Human Study حسب Dejan Juric, Jordi Rodón, Josep Tabernero, Filip Janků, Howard A. Burris, Jan H.M. Schellens, Mark R. Middleton, Jordan Berlin, Martin Schüler, Marta Gil-Martín, Hope S. Rugo, Ruth Seggewiß-Bernhardt, Alan Huang, Douglas Bootle, David Demanse, Lars Blumenstein, Christina Coughlin, Cornelia Quadt, José Baselga

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    <sup>89</sup>Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922

    <sup>89</sup>Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922 حسب Wouter B. Nagengast, Maarten A. de Korte, Thijs H. Oude Munnink, Hetty Timmer‐Bosscha, Wilfred F.A. den Dunnen, Harry Hollema, Johan R. de Jong, Michael Rugaard Jensen, Cornelia Quadt, Carlos Garcı́a-Echeverrı́a, Guus A.M.S. van Dongen, Marjolijn N. Lub–de Hooge, Carolien P. Schröder, Elisabeth G.E. de Vries

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in <i>PIK3CA</i> -Mutant Breast Cancer

    mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in <i>PIK3CA</i> -Mutant Breast Cancer حسب Moshe Elkabets, Sadhna Vora, Dejan Juric, Natasha Morse, Mari Mino‐Kenudson, Taru Muranen, Jessica J. Tao, Ana Bosch Campos, Jordi Rodón, Yasir H. Ibrahim, Violeta Serra, Vanessa Rodrik-Outmezguine, Saswati Hazra, Sharat Singh, Philip Kim, Cornelia Quadt, Manway Liu, Alan Huang, Neal Rosen, Jeffrey A. Engelman, Maurizio Scaltriti, José Baselga

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer

    Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer حسب Jordi Rodón, José Alejandro Pérez Fidalgo, Ian E. Krop, Howard A. Burris, Ángel Guerrero‐Zotano, Carolyn D. Britten, Carlos Becerra, Jan H.M. Schellens, Donald Richards, Martin Schüler, Maysa Abu‐Khalaf, Faye M. Johnson, Malcolm Ranson, Jeff Edenfield, Antonio P. Silva, Wolfgang Hackl, Cornelia Quadt, David Demanse, Vincent Duval, José Baselga

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

    Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor حسب Dejan Juric, Pau Castel, Malachi Griffith, Obi L. Griffith, Helen Won, Haley Ellis, Saya H. Ebbesen, Benjamin J. Ainscough, Avinash Ramu, Gopa Iyer, Ronak Shah, Tiffany G. Huynh, Mari Mino‐Kenudson, Dennis C. Sgroi, Steven J. Isakoff, Ashraf Thabet, Leila Elamine, David B. Solit, Scott W. Lowe, Cornelia Quadt, Malte Peters, Adnan Derti, Robert Schegel, Alan Huang, Elaine R. Mardis, Michael F. Berger, José Baselga, Maurizio Scaltriti

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers

    Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers حسب Stéphane Ferretti, Jacques Hamon, Ruben de Kanter, Clemens Scheufler, Rita Andraos-Rey, Stéphanie Barbé, Elisabeth Bechter, Jutta Blank, Vincent Bordas, Ernesta Dammassa, Eric A. Decker, Noemi Di Nanni, Marion Dourdoigne, Elena Gavioli, Marc Hattenberger, Alisa Heuser, Christelle Hemmerlin, Jürgen Hinrichs, Gráinne Kerr, Laurent Laborde, Isabel Jaco, Eloísa Jiménez Núñez, Hans‐Joerg Martus, Cornelia Quadt, Markus Reschke, Vincent Romanet, Fanny Schaeffer, Joseph Schoepfer, Maxime Schrapp, Ross Strang, Hans Voshol, Markus Wartmann, Sarah Welly, Frédéric J. Zécri, Francesco Hofmann, Henrik Möbitz, Marta Cortés-Cros

    منشور في 2024
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: